Investor Hub

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases.

Latest investor presentation
Latest clinical presentation
Latest quarterly earnings
Annual report
Global ticker
NASDAQNVAX
NASDAQNVAX
FormDescriptionDateFormat
DEF 14AOfficial notification to shareholders of matters to be brought to a vote ("Proxy")Mar 29, 2005Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in HTML.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in DOC file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in PDF file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in XLS file.
PRER14AProxy soliciting materials. Revised preliminary materialMar 25, 2005Open Proxy soliciting materials. Revised preliminary material in HTML.Open Proxy soliciting materials. Revised preliminary material in DOC file.Open Proxy soliciting materials. Revised preliminary material in PDF file.Open Proxy soliciting materials. Revised preliminary material in XLS file.
DFAN14AAdditional proxy soliciting materials filed by non-managementMar 23, 2005Open Additional proxy soliciting materials filed by non-management in HTML.Open Additional proxy soliciting materials filed by non-management in DOC file.Open Additional proxy soliciting materials filed by non-management in PDF file.Open Additional proxy soliciting materials filed by non-management in XLS file.
PREC14APreliminary proxy statement containing contested solicitationsMar 22, 2005Open Preliminary proxy statement containing contested solicitations in HTML.Open Preliminary proxy statement containing contested solicitations in DOC file.Open Preliminary proxy statement containing contested solicitations in PDF file.Open Preliminary proxy statement containing contested solicitations in XLS file.
PRER14AProxy soliciting materials. Revised preliminary materialMar 18, 2005Open Proxy soliciting materials. Revised preliminary material in HTML.Open Proxy soliciting materials. Revised preliminary material in DOC file.Open Proxy soliciting materials. Revised preliminary material in PDF file.Open Proxy soliciting materials. Revised preliminary material in XLS file.
PRE 14AA preliminary proxy statement providing notification matters to be brought to a voteMar 10, 2005Open A preliminary proxy statement providing notification matters to be brought to a vote in HTML.Open A preliminary proxy statement providing notification matters to be brought to a vote in DOC file.Open A preliminary proxy statement providing notification matters to be brought to a vote in PDF file.Open A preliminary proxy statement providing notification matters to be brought to a vote in XLS file.
Why invest with us

We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

For much of my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges, including HIV. Novavax is uniquely positioned to help end this pandemic with our protein-based vaccine. I believe in NVX-CoV2373 so much.

I came out of retirement to join the fight.

Lisa Dunkle
Vice President, Global Medical Lead for Coronavirus Vaccine

Get notifications for investor updates

Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.

Go to email subscription 

Investor inquiries

Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at ir@novavax.com

Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.